Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 10;8(2):3029-3041.
doi: 10.18632/oncotarget.13823.

Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application

Affiliations

Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application

Fangfang Chen et al. Oncotarget. .

Abstract

Introduction: Circulating tumor cells (CTCs) play a crucial role in cancer metastasis. In this study, we introduced a novel isolation method by size of epithelial tumor cells (ISET) device with automatic isolation and staining procedure, named one-stop ISET (osISET) and validated its feasibility to capture CTCs from cancer patients. Moreover, we aim to investigate the correlation between clinicopathologic features and CTCs in colorectal cancer (CRC) in order to explore its clinical application.

Results: The capture efficiency ranged from 80.3% to 88% with tumor cells spiked into medium while 67% to 78.3% with tumor cells spiked into healthy donors' blood. In detection blood samples of 72 CRC patients, CTCs and clusters of circulating tumor cells (CTC-clusters) were detected with a positive rate of 52.8% (38/72) and 18.1% (13/72) respectively. Moreover, CTC positive rate was associated with factors of lymphatic or venous invasion, tumor depth, lymph node metastasis and TNM stage in CRC patients (p < 0.01). Lymphocyte count and neutrophil to lymphocyte ratio (NLR) were significantly different between CTC positive and negative groups (p < 0.01).

Materials and methods: The capture efficiency of the device was tested by spiking cancer cells (MCF-7, A549, SW480, Hela) into medium or blood samples of healthy donors. Blood samples of 72 CRC patients were detected by osISET device. The clinicopathologic characteristics of 72 CRC patients were collected and the association with CTC positive rate or CTC count were analyzed.

Conclusions: Our osISET device was feasible to capture and identify CTCs and CTC-clusters from cancer patients. In addition, our device holds a potential for application in cancer management.

Keywords: circulating tumor cells (CTCs); clusters of circulating tumor cells (CTC-clusters); colorectal cancer (CRC); epithelial-mesenchymal transition (EMT); isolation method by size of epithelial tumor cells (ISET).

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1. The results of capture efficiency tests
(A) The capture efficiencies of different tumor cells sipked into DMEM or blood samples. (B) Captured SW480 cell number against the number of spiked in DMEM or blood samples at different concentrations. The error bars represent a mean ± standard deviation from three repeats. (C) Wright's staining of captured MCF-7, A549, SW480 and Hela cells. The arrows indicated tumor cells and the triangle (▲) indicated white blood cells (WBCs).
Figure 2
Figure 2. The images of IF staining and Wright's staining for the same samples
MCF-7 tumor cells spiked into healthy blood samples were set as positive control. CK+/CD45-/Hoechst+ cell was scored as CTCs and CK-/CD45+/Hoechst+ cell as WBCs.
Figure 3
Figure 3. The detection results of blood samples from 15 cancer patients
(A) Images of Wright's staining for isolated CTCs and CTC clusters from cancer patients. (B) The number of captured CTCs and CTC clusters in blood samples from 15 cancer patients. The arrows indicated CTCs and the triangle (▲) indicated WBCs.
Figure 4
Figure 4. Detection results of CTCs and CTC clusters in different stages of 72 CRC patients
Figure 5
Figure 5. Correlationship of CTC counts with number of lymphocytes and NLR
Figure 6
Figure 6. Introduction of the osISET device
(A) The blood samples were waiting for isolation. (B) The filter membrane picked by the forceps was at the bottom of a cylindrical filtration. (C) The calibrated 8-μm-diameter pores were shown. (D) The transparent filter membrane was placed on slide after automated isolation.

Similar articles

Cited by

References

    1. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006;33:S9–14. - PubMed
    1. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218–4224. - PubMed
    1. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10:233–239. - PMC - PubMed
    1. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–1229. - PubMed
    1. Mateo J, Gerlinger M, Rodrigues DN, de Bono JS. The promise of circulating tumor cell analysis in cancer management. Genome Biol. 2014;15:448. - PMC - PubMed

MeSH terms

LinkOut - more resources